

Specialty Certificate Examination (SCE) in Medical Oncology 2024 Selected Examination Metrics

The 2024 SCE in Medical Oncology was sat in September 2024 by 237 candidates of whom 104 were self-declared UK resident doctors. From 2022 'OTH' self-declared UK resident doctors are excluded from UK resident doctors' cohort.

Candidates who did not declare their training details and the OTH group are reported as 'Other' (133).


Pass Mark

The 2024 Medical Oncology examination was equated using 2019 UK resident doctors' performance, excluding OTH group, in line with all the other SCEs. The standards of the examination were reviewed in November 2022 and the pass score is maintained to **371**. All future examinations will use 371 as the passing score until the standards are reviewed by the SCE Medical Oncology Examination Board.

For the 2024 SCE Medical Oncology examination the pass mark was set at **371 (57% or 114/200)**.

UK resident doctors' performance


In 2024 ST5 UK resident doctors had the highest sitting number (41) and a pass rate of 87.8%. The pass rate for all UK resident doctors was 82.7% and for all candidates 74.3%.



The numbers at the top of the bars are the number of resident doctors sitting.


Topic performance

In 2024 UK resident doctors had their highest percentage of correct answers in CNS cancer (81.3%) and their lowest in Leukaemia (47.1%). There are very few questions in these two topics.



Data labels on the chart represent the number of questions per topic

In 2024 Other candidates had their highest percentage of correct answers in CNS cancer (87.5%) and their lowest in Prostate cancer (44.7%). There are very few questions in these two topics.



Data labels on the chart represent the number of questions per topic

MRCP(UK) Research unit
January 2025